4//SEC Filing
Gamble Carol A 4
Accession 0001232524-12-000025
CIK 0001232524other
Filed
Jan 17, 7:00 PM ET
Accepted
Jan 18, 8:12 PM ET
Size
22.1 KB
Accession
0001232524-12-000025
Insider Transaction Report
Form 4
Gamble Carol A
SVP, GC and Secretary
Transactions
- Disposition to Issuer
Incentive Stock Option (right to buy)
2012-01-18−2,229→ 0 totalExercise: $1.25Exp: 2019-01-20→ Common Stock (2,229 underlying) - Disposition to Issuer
Incentive Stock Option (right to buy)
2012-01-18−14,961→ 0 totalExercise: $11.48Exp: 2020-03-07→ Common Stock (14,961 underlying) - Disposition to Issuer
Incentive Stock Option (right to buy)
2012-01-18−4,845→ 0 totalExercise: $30.18Exp: 2014-02-17→ Common Stock (4,845 underlying) - Disposition to Issuer
Common Stock
2012-01-18−82,213→ 0 total - Disposition to Issuer
Incentive Stock Option (right to buy)
2012-01-18−14,538→ 0 totalExercise: $15.09Exp: 2014-02-17→ Common Stock (14,538 underlying) - Disposition to Issuer
Incentive Stock Option (right to buy)
2012-01-18−4,845→ 0 totalExercise: $45.27Exp: 2014-02-17→ Common Stock (4,845 underlying) - Disposition to Issuer
Incentive Stock Option (right to buy)
2012-01-18−3,752→ 0 totalExercise: $7.96Exp: 2018-05-15→ Common Stock (3,752 underlying) - Disposition to Issuer
Incentive Stock Option (right to buy)
2012-01-18−11,579→ 0 totalExercise: $19.37Exp: 2017-02-26→ Common Stock (11,579 underlying)
Footnotes (8)
- [F1]Disposition made in connection with the conversion of securities in the merger (the "Merger") pursuant to the Agreement and Plan of Merger and Reorganization by and among Jazz Pharmaceuticals plc (formerly Azur Pharma Public Limited Company), Jaguar Merger Sub Inc., Jazz Pharmaceuticals, Inc. and Seamus Mulligan, solely in his capacity as indemnitors' representative. The effective date of the Merger is January 18, 2012. This report is being filed by the Reporting Person solely to report the disposition of securities of Jazz Pharmaceuticals, Inc. made in connection with the Merger. The Reporting Person will file a separate Form 4 to reflect the corresponding acquisition of securities of Jazz Pharmaceuticals plc made in connection with the Merger.
- [F2]Shares of common stock converted in connection with the Merger into an equal number of ordinary shares of Jazz Pharmaceuticals plc having a market value, based on the closing price of Jazz Pharmaceuticals plc's ordinary shares on the effective date of the Merger, of $47.34 per share.
- [F3]This option vested one fourth on February 18, 2005, one eighth on August 18, 2005, and the remainder in 30 equal monthly installments thereafter.
- [F4]This option has a vesting schedule of one third vested on February 27, 2010 and the remainder vesting in 24 equal monthly installments thereafter.
- [F5]This option has a vesting schedule of one half vested on April 8, 2010 and the remainder vesting in 24 equal monthly installments thereafter.
- [F6]This option has a vesting schedule of one third vested on January 21, 2010 and the remainder vesting in 24 equal monthly installments thereafter.
- [F7]This option has a vesting schedule of one fourth vested on March 8, 2011 and the remainder vesting in 36 equal monthly installments thereafter.
- [F8]Options assumed/converted in connection with the Merger into options to acquire the same number of ordinary shares of Jazz Pharmaceuticals plc at the same exercise price and on substantially the same terms.
Documents
Issuer
Jazz Pharmaceuticals plc
CIK 0001232524
Entity typeother
Related Parties
1- filerCIK 0001397267
Filing Metadata
- Form type
- 4
- Filed
- Jan 17, 7:00 PM ET
- Accepted
- Jan 18, 8:12 PM ET
- Size
- 22.1 KB